Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS: In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy. Crossover from the chemotherapy group to the pembrolizumab group was permitted in the event of disease progression. The primary end point, progression-free survival, was assessed by means of blinded, independent, central radiologic review. Secondary end points were overall survival, objective response rate, and safety. RESULTS: Median progression-free survival was 10.3 months (95% confidence interval [CI], 6.7 to not reached) in the pembrolizumab group versus 6.0 months (95% CI, 4.2 to 6.2) in the chemotherapy group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.37 to 0.68; P<0.001). The estimated rate of overall survival at 6 months was 80.2% in the pembrolizumab group versus 72.4% in the chemotherapy group (hazard ratio for death, 0.60; 95% CI, 0.41 to 0.89; P=0.005). The response rate was higher in the pembrolizumab group than in the chemotherapy group (44.8% vs. 27.8%), the median duration of response was longer (not reached [range, 1.9+ to 14.5+ months] vs. 6.3 months [range, 2.1+ to 12.6+]), and treatment-related adverse events of any grade were less frequent (occurring in 73.4% vs. 90.0% of patients), as were grade 3, 4, or 5 treatment-related adverse events (26.6% vs. 53.3%). CONCLUSIONS: In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. (Funded by Merck; KEYNOTE-024 ClinicalTrials.gov number, NCT02142738 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, ICIs are also associated with frequent and potentially organ- or life-threatening immune-related adverse events (irAEs), which generally mimic autoimmune or inflammatory conditions”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“indeed, up to 90% of patients treated with ipilimumab and up to 70% of those treated with PD-1/PD-L1 antibodies experience at least one irAE).3,4”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial trials on anti-PD-1 and anti-PD-L1 inhibitors reported a significant association between pre-treatment intratumoral PD-L1 expression and response to treatment in a variety of tumor types including melanoma and NSCLC”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Reck et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Research works printed but not linked: 1
- Xiao HQ, 2016, Onco Targets Ther, 9, 1471
Cited by
Items 501–600 of 1,054
Alva, A. S., Mangat, P. K., Garrett-Mayer, E., Halabi, S., Hansra, D., Calfa, C. J., Khalil, M. F., Ahn, E. R., Cannon, T. L., Crilley, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02923 · Cited by 181
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot, J. M., Lazarovici, J., Tieu, A., Champiat, S., Voisin, A. L., Ebbo, M., Godeau, B., Michel, M., Ribrag, V., & Lambotte, O. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.014 · Cited by 180
Yang, J. C.-H., Gadgeel, S. M., Sequist, L. V., Wu, C.-L., Papadimitrakopoulou, V. A., Su, W.-C., Fiore, J., Saraf, S., Raftopoulos, H., & Patnaik, A. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.028 · Cited by 180
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
Wang, S., Cowley, L. A., & Liu, X.-S. (2019) · Molecules · doi:10.3390/molecules24183214 · Cited by 180
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
Della Corte, C. M., Sen, T., Gay, C. M., Ramkumar, K., Diao, L., Cardnell, R. J., Rodriguez, B. L., Stewart, C. A., Papadimitrakopoulou, V. A., Gibson, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.009 · Cited by 180
Kabacaoglu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 179
Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
Lichtenegger, F. S., Rothe, M., Schnorfeil, F. M., Deiser, K., Krupka, C., Augsberger, C., Schlüter, M., Neitz, J., & Subklewe, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00385 · Cited by 179
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Arafat Hossain, M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 178
Chen, Y., Gao, M., Huang, Z., Yu, J., & Meng, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00940-z · Cited by 178
Endocrine side effects of cancer immunotherapy
Cukier, P., Santini, F. C., Scaranti, M., & Hoff, A. O. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0358 · Cited by 177
Ricciuti, B., Recondo, G., Spurr, L. F., Li, Y. Y., Lamberti, G., Venkatraman, D., Umeton, R., Cherniack, A. D., Nishino, M., Sholl, L. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3529 · Cited by 151
Fumet, J.-D., Richard, C., Ledys, F., Klopfenstein, Q., Joubert, P., Routy, B., Truntzer, C., Gagné, A., Hamel, M.-A., Guimaraes, C. F., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0220-9 · Cited by 176
Chen, X., Gao, A., Zhang, F., Yang, Z., Wang, S., Fang, Y., Li, J., Wang, J., Shi, W., Wang, L., et al. (2021) · Theranostics · doi:10.7150/thno.52435 · Cited by 176
Uryvaev, A., Passhak, M., Hershkovits, D., Sabo, E., & Bar-Sela, G. (2018) · Medical Oncology · doi:10.1007/s12032-018-1080-0 · Cited by 176
Hinterleitner, C., Strähle, J., Malenke, E., Hinterleitner, M., Henning, M., Seehawer, M., Bilich, T., Heitmann, J., Lutz, M., Mattern, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27303-7 · Cited by 175
Inhibitors of the PD-1 Pathway in Tumor Therapy
LaFleur, M. W., Muroyama, Y., Drake, C. G., & Sharpe, A. H. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701044 · Cited by 175
PD-L1 status in breast cancer: Current view and perspectives
Vranić, S., Cyprian, F. S., Gatalica, Z., & Palazzo, J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.003 · Cited by 177
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
To, K. K. W., Fong, W., & Cho, W. C. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.635007 · Cited by 175
The New Era of Immunotherapy in Gastric Cancer
Takei, S., Kawazoe, A., & Shitara, K. (2022) · Cancers · doi:10.3390/cancers14041054 · Cited by 176
Chen, J. H., Nieman, L. T., Spurrell, M., Jorgji, V., Elmelech, L., Richieri, P., Xu, K. H., Madhu, R., Parikh, M., Zamora, I., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01792-2 · Cited by 174
Leighl, N. B., Hellmann, M. D., Hui, R., Carcereny, E., Felip, E., Ahn, M.-J., Eder, J. P., Balmanoukian, A. S., Aggarwal, C., Horn, L., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30500-9 · Cited by 174
Self-citationLee, J. B., Kim, H. R., & Ha, S.-J. (2022) · Immune Network · doi:10.4110/in.2022.22.e2 · Cited by 174
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 174
Paz-Ares, L. G., Juan-Vidal, O., Mountzios, G. S., Felip, E., Reinmuth, N., de Marinis, F., Girard, N., Patel, V. M., Takahama, T., Owen, S. P., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00733 · Cited by 137
Xiong, A., Wang, L., Chen, J., Wu, L., Liu, B., Yao, J., Zhong, H., Li, J., Cheng, Y., Sun, Y., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02722-3 · Cited by 173
Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer
Bartolacci, C., Andreani, C., Vale, G., Berto, S., Melegari, M., Crouch, A. C., Baluya, D. L., Kemble, G., Hodges, K., Starrett, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31963-4 · Cited by 173
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
Majem, M., Juan, O., Insa, A., Reguart, N., Trigo, J. M., Carcereny, E., García-Campelo, R., García, Y., Guirado, M., & Provencio, M. (2019) · Clinical and Translational Oncology · doi:10.1007/s12094-018-1978-1 · Cited by 173
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
Ancevski Hunter, K., Socinski, M. A., & Villaruz, L. C. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0308-6 · Cited by 173
“2 Pembrolizumab In a phase III trial in the first-line setting, pembrolizumab was shown to significantly improve OS and PFS as compared to platinum-based chemotherapy in patients with over 50% expression of PD-L1 as assessed by the 22C3 pharmDx IHC assay (Dako) [10].”
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Diggs, L. P., & Hsueh, E. C. (2017) · Biomarker Research · doi:10.1186/s40364-017-0093-8 · Cited by 173
Schrock, A. B., Li, S. D., Frampton, G. M., Suh, J., Braun, E., Mehra, R., Buck, S. C., Bufill, J. A., Peled, N., Karim, N. A., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.03.005 · Cited by 173
“Recent studies have also reported that PSCs have high PD-L1 expression, which has been linked to improved response to ICPIs.(38) However, a subset of patients with low PD-L1 expression by IHC have benefited from ICPIs.”
ResultSelf-citationRationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Sato, H., Okonogi, N., & Nakano, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01666-1 · Cited by 173
Immunotherapy for pancreatic cancer: Barriers and breakthroughs
Torphy, R. J., Zhu, Y., & Schulick, R. D. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12176 · Cited by 152
Chen, S., Zhang, Z., Zheng, X., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Qian, Y., Cui, P., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.562315 · Cited by 174
Assoun, S., Theou-Anton, N., Nguenang, M., Cazes, A., Danel, C., Abbar, B., Pluvy, J., Gounant, V., Khalil, A., Namour, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.005 · Cited by 172
PD-L1 expression testing in non-small cell lung cancer
Teixidó, C., Vilariño, N., Reyes, R., & Reguart, N. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918763493 · Cited by 156
Rasul, M. F., Hussen, B. M., Salihi, A., Ismael, B. S., Jalal, P. J., Zanichelli, A., Jamali, E., Baniahmad, A., Ghafouri-Fard, S., Basiri, A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01487-4 · Cited by 171
Bamodu, O. A., Kuo, K.-T., Wang, C.-H., Huang, W.-C., Wu, A. T. H., Tsai, J.-T., Lee, K.-Y., Yeh, C.-T., & Wang, L.-S. (2019) · Nutrients · doi:10.3390/nu11102264 · Cited by 171
D’Souza, M., Nielsen, D., Svane, I. M., Iversen, K., Rasmussen, P. V., Madelaire, C., Fosbøl, E., Køber, L., Gustafsson, F., Andersson, C., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa884 · Cited by 171
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 170
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
Anagnostou, V., Ho, C., Nicholas, G., Juergens, R. A., Sacher, A., Fung, A. S., Wheatley-Price, P., Laurie, S. A., Levy, B., Brahmer, J. R., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02598-9 · Cited by 170
Self-citationOwada-Ozaki, Y., Muto, S., Takagi, H., Inoue, T., Watanabe, Y., Fukuhara, M., Yamaura, T., Okabe, N., Matsumura, Y., Hasegawa, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.003 · Cited by 170
“The KEYNOTE 024 trial of first-line pembrolizumab for treatment of NSCLC showed that patients with a high level of PD-L1 expression ( 50%) in the tumor had a clear survival benefit.(1) Subgroup analysis of the Checkmate 026 trial of first-line nivolumab for treatment of NSCLC showed that tumor mutation burden (TMB), as”
MethodMunari, E., Zamboni, G., Lunardi, G., Marchionni, L., Marconi, M., Sommaggio, M., Brunelli, M., Martignoni, G., Netto, G. J., Hoque, M. O., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.017 · Cited by 170
“Food and Drug Administration approved the anti–PD-1 pembrolizumab as a single agent for patients with tumors expressing PD-L1 in at least 50% of neoplastic cells for first-line therapy and as a second-line therapy for patients whose tumors express PD-L1 in at least 1% of cells.(7,8) Moreover, although some studies hav…”
BackgroundMeder, L., Schuldt, P., Thelen, M., Schmitt, A., Dietlein, F., Klein, S., Borchmann, S., Wennhold, K., Vlasic, I., Oberbeck, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2176 · Cited by 170
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
Dougan, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01547 · Cited by 170
“A relatively high frequency of patients treated with PD-1/PD-L1 blockade develop low-grade diarrhea, but this rarely progresses to severe colitis (3, 7, 9, 26, 28, 53) (Figure 3).”
BackgroundRole of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment
Menon, H., Ramapriyan, R., Cushman, T. R., Verma, V., Kim, H. H., Schoenhals, J. E., Atalar, S. C., Selek, U., Chun, S. G., Chang, J. Y., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00193 · Cited by 171
Miret, J. J., Kirschmeier, P. T., Koyama, S., Zhu, M., Li, Y. Y., Naito, Y., Wu, M., Malladi, V. S., Huang, W., Walker, W., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0504-5 · Cited by 171
Lim, R. J., Salehi‐Rad, R., Tran, L. M., Oh, M. S., Dumitras, C., Crosson, W. P., Li, R., Patel, T. S., Man, S., Yean, C. E., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101479 · Cited by 173
NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis
Lurienne, L., Cervesi, J., Duhalde, L., de Gunzburg, J., Andremont, A., Zalcman, G., Buffet, R., & Bandinelli, P.-A. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.002 · Cited by 169
The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances
Janopaul-Naylor, J. R., Shen, Y., Qian, D. C., & Buchwald, Z. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011061 · Cited by 169
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses
Oliver, A. J., Lau, P. K. H., Unsworth, A. S., Loi, S., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00070 · Cited by 169
“Besides, ICI have also established efficacy in a range of other solid tumors such as non-small cell lung cancer (NSCLC) (33, 34) and renal cell carcinoma (35).”
BackgroundInfluentialRemon, J., Passiglia, F., Ahn, M.-J., Barlesi, F., Forde, P. M., Garon, E. B., Gettinger, S., Goldberg, S. B., Herbst, R. S., Horn, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.006 · Cited by 169
Self-citationMathieu, L. N., Shah, S., Pai-Scherf, L. H., Larkins, E. A., Vallejo, J. J., Li, X., Rodríguez, L., Mishra-Kalyani, P. S., Goldberg, K. B., Kluetz, P. G., et al. (2021) · The Oncologist · doi:10.1002/onco.13752 · Cited by 169
Magee, D. E., Hird, A. E., Klaassen, Z., Sridhar, S. S., Nam, R. K., Wallis, C. J. D., & Kulkarni, G. S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.008 · Cited by 168
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 168
written on behalf of AME Lung Cancer Collaborative Group, Xu, Y., Wan, B., Chen, X., Zhan, P., Zhao, Y., Zhang, T., Liu, H., Afzal, M. Z., Dermime, S., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.08.09 · Cited by 168
Wang, S., Wu, Q., Chen, T., Su, R., Pan, C., Qian, J., Huang, H., Yin, S., Xie, H., Zhou, L., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.011 · Cited by 168
Lazăr, D. C., Avram, M. F., Romosan, I., Cornianu, M., Tăban, S. M., & Goldiș, A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i32.3583 · Cited by 168
Tian, P., He, B., Mu, W., Liu, K., Liu, L., Zeng, H., Liu, Y., Jiang, L., Zhou, P., Huang, Z., et al. (2021) · Theranostics · doi:10.7150/thno.48027 · Cited by 155
Caini, S., Riccio, M. D., Vettori, V., Scotti, V., Martinoli, C., Raimondi, S., Cammarata, G., Palli, D., Banini, M., Masala, G., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.12.005 · Cited by 168
Cook, S., Samuel, V., Meyers, D. E., Stukalin, I., Litt, I., Sangha, R., Morris, D. G., Heng, D. Y. C., Pabani, A., Dean, M., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.52302 · Cited by 167
B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
Yonesaka, K., Haratani, K., Takamura, S., Sakai, H., Kato, R., Takegawa, N., Takahama, T., Tanaka, K., Hayashi, H., Takeda, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2852 · Cited by 167
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Landi, L., D’Incà, F., Gelibter, A., Chiari, R., Grossi, F., Delmonte, A., Passaro, A., Signorelli, D., Gelsomino, F., Galetta, D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0793-8 · Cited by 167
Comorbidities in the management of patients with lung cancer
Leduc, C., Antoni, D., Charloux, A., Falcoz, P., & Quoix, É. (2017) · European Respiratory Journal · doi:10.1183/13993003.01721-2016 · Cited by 167
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab
Peters, S., Kerr, K. M., & Stahel, R. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.002 · Cited by 155
Radiation Pneumonitis: Old Problem, New Tricks
Jain, V., & Berman, A. T. (2018) · Cancers · doi:10.3390/cancers10070222 · Cited by 167
Sintilimab: A Promising Anti-Tumor PD-1 Antibody
Zhang, L., Mai, W., Jiang, W., & Geng, Q. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.594558 · Cited by 167
Immunotherapy for Advanced Non–Small Cell Lung Cancer: A Decade of Progress
Shields, M. D., Marin-Acevedo, J. A., & Pellini, B. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321483 · Cited by 167
Genomic instability, inflammatory signaling and response to cancer immunotherapy
Chen, M., Linstra, R., & van Vugt, M. A. T. M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188661 · Cited by 166
Sehgal, K., Gill, R. R., Widick, P., Bindal, P., McDonald, D. C., Shea, M., Rangachari, D., & Costa, D. B. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.37120 · Cited by 166
Russo, A., Russano, M., Franchina, T., Migliorino, M. R., Aprile, G., Mansueto, G., Berruti, A., Falcone, A., Aieta, M., Gelibter, A., et al. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01229-w · Cited by 166
Advances in Cancer Immunotherapy in Solid Tumors
Menon, S., Shin, S., & Dy, G. (2016) · Cancers · doi:10.3390/cancers8120106 · Cited by 166
Zhu, J., Armstrong, A. J., Friedlander, T. W., Kim, W. K., Pal, S. K., George, D. J., & Zhang, T. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0314-1 · Cited by 167
Emerging therapies for non-small cell lung cancer
Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 168
Brandum, E. P., Jørgensen, A. S., ROSENKILDE, M. M., & Hjortø, G. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158340 · Cited by 168
Yang, J. C.-H., Lee, D. H., Lee, J.-S., Fan, Y., de Marinis, F., Iwama, E., Inoue, T., Rodríguez-Cid, J., Zhang, L., Yang, C.-T., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02747 · Cited by 165
Self-citationMismatch repair deficiency is not sufficient to elicit tumor immunogenicity
Westcott, P. M. K., Muyas, F., Hauck, H., Smith, O. C., Sacks, N. J., Ely, Z. A., Jaeger, A. M., Rideout, W. M., Zhang, D., Bhutkar, A., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01499-4 · Cited by 165
Advances in immune checkpoint inhibitors for bone sarcoma therapy
Thanindratarn, P., Dean, D. C., Nelson, S. D., Hornicek, F. J., & Duan, Z. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100221 · Cited by 165
Blumenthal, G. M., Gong, Y., Kehl, K., Mishra-Kalyani, P., Goldberg, K. B., Khozin, S., Kluetz, P. G., Oxnard, G. R., & Pazdur, R. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz060 · Cited by 165
Middleton, G., Brock, K., Savage, J., Mant, R., Summers, Y., Connibear, J., Shah, R., Ottensmeier, C., Shaw, P., Lee, S.-M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30033-3 · Cited by 165
Strategies for Increasing Pancreatic Tumor Immunogenicity
Johnson, B. A., Yarchoan, M., Lee, V., Laheru, D. A., & Jaffee, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2318 · Cited by 165
Personalized therapy for lung cancer: Striking a moving target
Pakkala, S., & Ramalingam, S. S. (2018) · JCI Insight · doi:10.1172/jci.insight.120858 · Cited by 151
Kim, J. Y., Kronbichler, A., Eisenhut, M., Hong, S. H., van der Vliet, H. J., Kang, J., Shin, J. I., & Gamerith, G. (2019) · Cancers · doi:10.3390/cancers11111798 · Cited by 165
Zhao, S., Gao, G., Li, W., Li, X., Zhao, C., Jiang, T., Jia, Y., He, Y., Li, A., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.017 · Cited by 164
Choucair, K., Morand, S., Stanbery, L., Edelman, G., Dworkin, L., & Nemunaitis, J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0174-y · Cited by 164
Pinto, J. A., Vallejos, C. S., Raez, L. E., Mas, L. A., Ruiz, R., Torres-Roman, J. S., Morante, Z., Araujo, J. M., Gómez, H. L., Aguilar, A., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000344 · Cited by 164
Durm, G. A., Jabbour, S. K., Althouse, S. K., Liu, Z., Sadiq, A. A., Zon, R. T., Jalal, S. I., Kloecker, G. H., Williamson, M. J., Reckamp, K. L., et al. (2020) · Cancer · doi:10.1002/cncr.33083 · Cited by 164
Targeting immune checkpoints in breast cancer: an update of early results
Solinas, C., Gombos, A., Latifyan, S., Piccart, M. J., Kok, M., & Buisseret, L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000255 · Cited by 166
Yamaguchi, T., Shimizu, J., Hasegawa, T., Horio, Y., Inaba, Y., Yatabe, Y., & Hida, T. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.001 · Cited by 148
Proto, C., Ferrara, R., Signorelli, D., Russo, G. L., Galli, G., Imbimbo, M., Prelaj, A., Zilembo, N., Ganzinelli, M., Pallavicini, L. M., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.03.004 · Cited by 164
Ferrara, R., Mezquita, L., Auclin, E., Chaput, N., & Besse, B. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.003 · Cited by 163
Wang, Q., Li, M., Yang, M., Yang, Y., Song, F., Zhang, W., Li, X., & Chen, K. (2020) · Aging · doi:10.18632/aging.102814 · Cited by 163
Mok, T., Nakagawa, K., Park, K., Ohe, Y., Girard, N., Kim, H. R., Wu, Y.-L., Gainor, J., Lee, S.-H., Chiu, C.-H., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01017 · Cited by 163
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
Salgia, R., Pharaon, R., Mambetsariev, I., Nam, A., & Sattler, M. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100186 · Cited by 163
Pseudoprogression and hyperprogression after checkpoint blockade
Wang, Q., Gao, J., & Wu, X. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.03.018 · Cited by 163
Soo, R. A., Lim, S. M., Syn, N. L., Teng, R., Soong, R., Mok, T. S. K., & Cho, B. C. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.009 · Cited by 153
Wang, D., Niu, X., Wang, Z., Song, C.-L., Huang, Z., Chen, K.-N., Duan, J., Bai, H., Xu, J., Zhao, J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1086 · Cited by 150
Mehnert, J. M., Bergsland, E. K., O’Neil, B. H., Santoro, A., Schellens, J. H. M., Cohen, R. B., Doi, T., Ott, P. A., Pishvaian, M. J., Puzanov, I. J., et al. (2020) · Cancer · doi:10.1002/cncr.32883 · Cited by 163
Rizzo, A., Santoni, M., Mollica, V., Logullo, F. O., Rosellini, M., Marchetti, A., Faloppi, L., Battelli, N., & Massari, F. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.2029405 · Cited by 163
Cardiovascular Toxicities Associated with Cancer Immunotherapies
Wang, D. Y., Okoye, G. D., Neilan, T. G., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 157
Khunger, M., Hernandez, A. V., Pasupuleti, V., Rakshit, S., Pennell, N. A., Stevenson, J., Mukhopadhyay, S., Schalper, K., & Velcheti, V. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00030 · Cited by 154
Metadata
- Authors
- Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leiby, M. A., Lubiniecki, G. M., Shentu, Y., Rangwala, R., & Brahmer, J. R.
- Affiliations
- The University of Sydney (AU)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-10
- Volume
- 375
- Issue
- 19
- Pages
- 1823-1833
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2527905628
- Cited by
- 10,089
- References
- 54
- Citations by year
- 2026: 584 · 2025: 750 · 2024: 913 · 2023: 1012 · 2022: 1108 · 2021: 1321 · 2020: 1324 · 2019: 1154 · 2018: 1132 · 2017: 724 · 2016: 46
- FWCI
- 548.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- pembrolizumab, PD-L1-positive non-small cell lung cancer, PD-1 inhibitors, immune checkpoint inhibitors, platinum-based chemotherapy, progression-free survival, overall survival, objective response rate, treatment-related adverse events, EGFR wild-type, immunotherapy versus chemotherapy, duration of response
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Platinum Compounds, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.